Lee M L, Gale R P, Yap P L
International Quantitative Consultants, Inc., Glendale, California 91203, USA.
Annu Rev Med. 1997;48:93-102. doi: 10.1146/annurev.med.48.1.93.
Intravenous immunoglobulin (IVIG) concentrates were originally developed as replacement therapy for individuals with primary deficiencies of the immune system. However, in various well-designed, controlled clinical trials, the ability of IVIG to prevent and possibly treat infections in patients with secondary immune deficiencies has also been considered. In this review, we briefly consider these different applications and suggest whether the data are sufficient to employ IVIG in these clinical settings.
静脉注射免疫球蛋白（IVIG）浓缩物最初是作为免疫系统原发性缺陷个体的替代疗法而开发的。然而，在各种精心设计的对照临床试验中，IVIG预防和可能治疗继发性免疫缺陷患者感染的能力也受到了关注。在本综述中，我们简要探讨了这些不同的应用，并指出现有数据是否足以支持在这些临床环境中使用IVIG。
